337 related articles for article (PubMed ID: 11642476)
1. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
[TBL] [Abstract][Full Text] [Related]
2. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
[TBL] [Abstract][Full Text] [Related]
3. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
4. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Gambi F; De Berardis D; Campanella D; Carano A; Sepede G; Salini G; Mezzano D; Cicconetti A; Penna L; Salerno RM; Ferro FM
J Psychopharmacol; 2005 Sep; 19(5):483-7. PubMed ID: 16166185
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of irritability in pervasive developmental disorders.
Stigler KA; McDougle CJ
Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
[TBL] [Abstract][Full Text] [Related]
7. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
Roose SP; Nelson JC; Salzman C; Hollander SB; Rodrigues H;
Curr Med Res Opin; 2003; 19(8):737-46. PubMed ID: 14687445
[TBL] [Abstract][Full Text] [Related]
8. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder.
Coskun M; Karakoc S; Kircelli F; Mukaddes NM
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):203-6. PubMed ID: 19364298
[TBL] [Abstract][Full Text] [Related]
10. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.
Yoon SJ; Pae CU; Kim DJ; Namkoong K; Lee E; Oh DY; Lee YS; Shin DH; Jeong YC; Kim JH; Choi SB; Hwang IB; Shin YC; Cho SN; Lee HK; Lee CT
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1196-201. PubMed ID: 16624467
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.
Haapasalo-Pesu KM; Vuola T; Lahelma L; Marttunen M
J Child Adolesc Psychopharmacol; 2004; 14(2):175-84. PubMed ID: 15319015
[TBL] [Abstract][Full Text] [Related]
12. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
14. Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?
Fusar-Poli P; Matteo L; Luca de M; Politi P; Cortesi M; Carboni V
J Psychosom Res; 2007 Jan; 62(1):101. PubMed ID: 17188127
[No Abstract] [Full Text] [Related]
15. Mirtazapine for treatment-resistant depression: a preliminary report.
Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.
Corson AH; Barkenbus JE; Posey DJ; Stigler KA; McDougle CJ
J Clin Psychiatry; 2004 Nov; 65(11):1531-6. PubMed ID: 15554768
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Findling RL
J Clin Psychiatry; 2011 Sep; 72(9):1270-6. PubMed ID: 21813076
[TBL] [Abstract][Full Text] [Related]
18. Open-label study of olanzapine in children with pervasive developmental disorder.
Kemner C; Willemsen-Swinkels SH; de Jonge M; Tuynman-Qua H; van Engeland H
J Clin Psychopharmacol; 2002 Oct; 22(5):455-60. PubMed ID: 12352267
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.
Masi G; Cosenza A; Millepiedi S; Muratori F; Pari C; Salvadori F
CNS Drugs; 2009; 23(6):511-21. PubMed ID: 19480469
[TBL] [Abstract][Full Text] [Related]
20. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia.
Mrakotsky C; Masek B; Biederman J; Raches D; Hsin O; Forbes P; de Moor C; DeMaso DR; Gonzalez-Heydrich J
J Anxiety Disord; 2008; 22(1):88-97. PubMed ID: 17419001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
